Abstracts tagged "glucocorticoids"

Abstract Number: 0238 • ACR Convergence 2025
Real-World Effectiveness of Mepolizumab on Gastrointestinal Involvement in Eosinophilic Granulomatosis with Polyangiitis and Hypereosinophilic Syndrome: A Multicenter Retrospective Study
Alessia Gatti¹, Francesca Regola¹, Giulia Fontana², Jacopo Mora², Mario Andrea Piga³, Gianluca Moroncini³, Rossella Acquaviva⁴, Palma Carlucci⁴, Silvia Noviello⁴, Angelo Vacca⁴, Paolo Delvino⁵, Enrico Heffler⁶, Emanuele Nappi⁶, Jakub Moll⁷, Jan Schroeder⁷, Laura Losappio⁷, Federica Davanzo⁸, Roberto Padoan⁹, Paolo Cameli¹⁰, Edoardo Conticini¹¹, Greta Pacini¹², Alvise Berti¹², Lorenzo Vrola¹³, Paola Tomietto¹³, Benedetta Fazzi¹⁴, elena treppo¹⁵, Luca Quartuccio¹⁴, Jan Willem Cohen Tervaert¹⁶, Sabrina Arnold¹⁷, Prof. Dr. med. Peter Lamprecht¹⁸, Florence Roufosse¹⁹, Ilaria Cavazzana¹, Franco Franceschini²⁰, Giacomo Emmi²¹ and Paola Toniati²², ¹Rheumatology and Clinical Immunology Unit – ERN ReCONNET, ASST Spedali Civili of Brescia and University of Brescia, Brescia, Italy, ²Rheumatology and Clinical Immunology Unit – ERN ReCONNET, ASST Spedali Civili and University of Brescia, Brescia, Lombardia, Italy, ³Università Politecnica delle Marche and Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy, ⁴Section of Internal Medicine 'Guido Baccelli', Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari 'Aldo Moro', Bari, Italy, ⁵Rheumatology Unit, IRCCS San Gerardo dei Tintori, Monza, Italy, ⁶Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI) and Personalized Medicine, Asthma and Allergy, IRCCS Humanitas Research Hospital, Milano, Italy, ⁷Division of Allergy and Clinical Immunology, ASST GOM Niguarda, Milano, Italy, ⁸Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padova, Italy, ⁹Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padua, Italy, ¹⁰University of Siena, Siena, Italy, ¹¹Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Italy, Siena, Italy, ¹²Santa Chiara Hospital and University of Trento, Unit of Rheumatology, Trento, Italy, ¹³UCO Medicina Clinica, ASUGI, Cattinara Teaching Hospital, Trieste, Italy, ¹⁴Division of Rheumatology, Department of Medicine (DMED), University of Udine, Udine, Italy, ¹⁵Division of Rheumatology, Department of Medicine, University of Udine, Udine, Italy, ¹⁶University of Alberta, Edmonton, AB, Canada, ¹⁷Department of Rheumatology and Clinical Immunology, University of Lübeck, Lubeck, Germany, ¹⁸University of Lübeck, Lübeck, Germany, ¹⁹Department of Internal Medicine, Hôpital Universitaire de Bruxelles - Erasme, Université Libre de Bruxelles, Bruxelles, Belgium, ²⁰University of Brescia, Brescia, Brescia, Italy, ²¹Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy, ²²Rheumatology and Clinical Immunology Unit – ERN ReCONNET, ASST Spedali Civili of Brescia, Brescia, Lombardia, Italy
Background/Purpose: Eosinophilic gastrointestinal disorders (EGIDs) are a group of disorders characterized by marked eosinophilic infiltration of the gastrointestinal (GI) tract resulting in organ dysfunction and…
Abstract Number: 2469 • ACR Convergence 2025
Development of Consensus Statements on Glucocorticoid Use in Systemic Lupus Erythematosus
Heh Shiang Sheu¹, Wen Nan Huang¹, Yao-Fan Fang², Tai-Ju Lee³, Ling-Ying Lu⁴, Ming-Han Chen⁵, Der-Yuan Chen⁶, Fu-Chiang Yeh⁷, Yu-Wan Liao¹, Chang-Youh Tsai⁸, Tsu-Yi Hsieh¹, Song-Chou Hsieh⁹, Shue-Fen Luo², Yu-Jih Su¹⁰, Yeong-Jian Jan Wu¹¹ and Chun chi Lu¹², ¹Taichung Veterans General Hospital, Taichung, Taichung, Taiwan (Republic of China), ²Chang Gung Memorial Hospital, Taoyuan, Taoyuan, Taiwan (Republic of China), ³National Taiwan University Hospital Hsinchu Branch, Hsinchu City, Taiwan (Republic of China), ⁴Kaohsiung Veterans General Hospital, Kaohsiung, Kaohsiung, Taiwan (Republic of China), ⁵Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Taipei, Taiwan (Republic of China), ⁶China Medical University Hospital, Taichung, Taichung, Taiwan (Republic of China), ⁷Tri-Service General Hospital, Taipei, Taipei, Taiwan (Republic of China), ⁸Fu Jen Catholic University Hospital, New Taipei, New Taipei, Taiwan (Republic of China), ⁹National Taiwan Unuversity Hospital, Taipei City, Taiwan (Republic of China), ¹⁰Chang Gung Memorial Hospital, Kaohsiung, Kaohsiung, Taiwan (Republic of China), ¹¹Chang Gung Memorial Hospital, Chang Gung University, Taoyuan City, Taiwan (Republic of China), ¹²¹. Tri-Service General Hospital, Taipei, Taiwan ². Kaohsiung Veteran General Hospital, Kaohsiung, Taiwan, Taipei, Taiwan (Republic of China)
Background/Purpose: Systemic glucocorticoid (GC) therapy is indispensable for treating active systemic lupus erythematosus (SLE) and lupus nephritis (LN), while contributing significantly to comorbidities and irreversible…
Abstract Number: 1526 • ACR Convergence 2025
Guidance For Corticosteroid Tapering In Patients With Systemic Lupus Erythematosus: Results From An International Delphi Consensus Project
Ed Vital¹, George Bertsias², Andrea Doria³, Sindhu Johnson⁴, Sarah Mackie⁵, Sandra Navarra⁶, Bas Nijmeijer⁷, Ayobami Olojo⁷, Bernardo A. Pons-Estel⁸, Onno Teng⁹ and Jinoos Yazdany¹⁰, ¹University of Leeds, Leeds, England, United Kingdom, ²Rheumatology and Clinical Immunology, University Hospital of Heraklion and University of Crete Medical School and Foundation for Research and Technology-Hellas (FORTH), Infections and Immunity, Institute of Molecular Biology and Biotechnology, Heraklion, Greece, ³University of Padova, Padova, Italy, ⁴Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁵University of Leeds, Leeds, United Kingdom, ⁶University of Santo Tomas, Manila, Philippines, ⁷AstraZeneca, Cambridge, United Kingdom, ⁸Grupo Oroño - Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ⁹Leiden University Medical Center, Leiderdorp, Netherlands, ¹⁰UCSF, San Francisco, CA
Background/Purpose: Despite guidelines for SLE emphasizing the importance of tapering corticosteroids (CS), detailed recommendations on how to taper are limited. The purpose of this modified…
Abstract Number: 0743 • ACR Convergence 2025
Giant Cell Arteritis Relapse After Treatment with Two Months of Prednisone and 12 Months of Tocilizumab
David O'Dea¹, Guy Katz¹, Belen Arevalo Molina¹, Adam Jarvie², Mark Matza¹, Ana Fernandes¹, John Stone³ and Sebastian H Unizony⁴, ¹Massachusetts General Hospital, Boston, MA, ²Emory University School of Medicine, Atlanta, GA, ³Massachusetts General Hospital , Harvard Medical School, Concord, MA, ⁴Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The optimal duration of tocilizumab (TCZ) treatment for giant cell arteritis (GCA) is unclear. Observational studies have shown that 50-60% of patients relapse after…
Abstract Number: 0045 • ACR Convergence 2025
Genetic regulators of corticosteroid response in hepatic and adipose tissue and risk of adverse metabolic outcomes in patients with rheumatoid arthritis initiating glucocorticoids.
Thomas Riley¹, Bryant England², Austin Wheeler², Punyasha Roul³, Grant Cannon⁴, Brian Sauer⁵, Gary Kunkel⁶, Katherine Wysham⁷, Beth Wallace⁸, Andreas Reimold⁹, Gail Kerr¹⁰, Isaac Smith¹¹, John Richards¹², Iris Lee¹³, Mitchell Lazar¹, Wenxiang Hu¹⁴, Michael Levin¹⁵, Scott Damrauer¹⁵, Rui Xiao¹⁶, Tate Johnson², Ted Mikuls², Joshua Baker¹ and Michael George¹, ¹University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³UNMC, Omaha, NE, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁷VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁸Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁹Dallas VA Medical Center, Dallas, TX, ¹⁰Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹¹Duke University Hospital, Durham, NC, ¹²Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ¹³Washington University in St Louis, Saint Louis, MO, ¹⁴Guangzhou National Laboratory, Guangzhou, China (People's Republic), ¹⁵University of Pennsylvania / Corporal Michael J. Crescenz VAMC, Philadelphia, PA, ¹⁶Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Previous studies identified single nucleotide polymorphisms (SNPs) that affect hepatocyte and adipocyte response to glucocorticoids (GCs). We aimed to determine if these candidate SNPs…
Abstract Number: 2273 • ACR Convergence 2025
Impact of Upadacitinib on Glucocorticoid Reduction in Patients with Moderate-to-Severe RA Who Achieved and Maintained Clinical Remission in the 2-Year UPHOLD Study
FRANK BUTTGEREIT¹, Andrew Ostor², Philip Conaghan³, Ana Romero⁴, Ivan Lagunes⁵, Andrew Garrison⁶, Tianming Gao⁷ and Suzan Attar⁸, ¹Charité University Medicine Berlin, Berlin, Berlin, Germany, ²Australian National University, Canberra, Australia, ³University of Leeds, Leeds, United Kingdom, ⁴AbbVie, Barcelona, Spain, ⁵Abbvie Inc, North Chicago, IL, ⁶AbbVie, USA, North Chicago, IL, ⁷AbbVie, North Chicago, IL, ⁸King Abdulaziz University, Saudi Arabia, Jeddah, Saudi Arabia

Background/Purpose: Glucocorticoids (GCs) are fast-acting drugs used to support csDMARD therapy for RA, but should be used sparingly and for short periods.1 Upadacitinib, an oral…
Abstract Number: 1355 • ACR Convergence 2025
Use of parenteral compared to oral glucocorticoids in early rheumatoid arthritis is superior for chance ofbeing off steroids and escalation of therapy at 1 year
Andreu Fernandez Codina¹, Marie-France Valois², Susan J. Bartlett³, Mishquatul Wahed⁴, Hugues Allard-Chamard⁵, Louis Bessette⁶, Glen Hazlewood⁷, Carol Hitchon⁸, Bindee Kuriya⁹, Vivian Bykerk¹⁰ and Janet Pope¹¹, ¹Western University, London, ON, Canada, ²McGill University, Pointe-Claire, QC, Canada, ³McGill University, Beaconsfield, QC, Canada, ⁴Western University, Windsor, ON, Canada, ⁵Université de Sherbrooke, Sherbrooke, Canada, ⁶Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹University of Toronto - Toronto, Toronto, ON, Canada, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹University of Western Ontario, London, ON, Canada
Background/Purpose: The 2023 EULAR recommendations for the management of Rheumatoid Arthritis (RA) emphasizes theimportance of limiting the dose and duration of glucocorticoids (GC) used in…
Abstract Number: 0739 • ACR Convergence 2025
Tocilizumab in Giant Cell Arteritis with ischemic vs non-ischemic manifestations
Carmen Secada-Gómez¹, Javier Loricera², Clara Moriano³, Santos Castañeda⁴, Javier Narváez⁵, Vicente Aldasoro Cáceres⁶, Olga Maiz⁷, Rafael B. Melero-González⁸, Paloma Vela Casasempere⁹, Susana Romero-Yuste¹⁰, Jose Luis Callejas¹¹, Eugenio de Miguel¹², Eva Galíndez Agirregoikoa¹³, Francisca Sivera¹⁴, Ivan Ferraz Amaro¹⁵, Julio Sánchez Martín¹⁶ and Ricardo Blanco¹, ¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Hospital León, LEON, Castilla y Leon, Spain, ⁴Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ⁵Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Hospital Universitario de Navarra, Pamplona, Spain, ⁷Hospital Universitario de Donosti, Donostia, Spain, ⁸COMPLEXO HOSPITALARIO UNIVERSITARIO DE OURENSE, O Carballino, Spain, ⁹Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, ¹⁰University Hospital Complex of Pontevedra, Pontevedra, Spain, ¹¹Department of Internal Medicine, Hospital San Cecilio, Granada, Spain, ¹²Hospital Universitario La Paz, Madrid, Spain, ¹³BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ¹⁴Hospital General Universitario Elda, Elda, Spain, ¹⁵Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹⁶Hospital Universitario ¹² de Octubre, Madrid, Spain
Background/Purpose: Tocilizumab (TCZ) is the only approved biological drug in the treatment of giant cell arteritis (GCA). However, there are no comparative studies on the…
Abstract Number: 0203 • ACR Convergence 2024
Agreement of Administrative Pharmacy Dispensing with Patient-Reported Use of Oral Glucocorticoids in a Rheumatoid Arthritis Cohort
Beth Wallace¹, Bryant England², Joshua Baker³, Sauer brian⁴, Jorge Rojas⁵, Punyasha Roul⁶, Michael George⁷, Katherine Wysham⁸, Hannah Brubeck⁹, Isaac Smith¹⁰, Liron Caplan¹¹, Paul Monach¹², Gail Kerr¹³, Gary Kunkel¹⁴, Tawnie Braaten¹⁵, Ted Mikuls² and grant Cannon¹⁶, ¹Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ²University of Nebraska Medical Center, Omaha, NE, ³Department of Medicine, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA, ⁴Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁵Seattle VA, Mexico, Mexico, ⁶UNMC, Omaha, NE, ⁷University of Pennsylvania, Philadelphia, PA, ⁸VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁹VA Puget Sound Health Care System, Seattle, WA, ¹⁰Duke Department of Medicine; VA Durham Healthcare System, Durham, NC, ¹¹Univ of Colorado School of Medicine/Rocky Mtn Regional Veterans Affairs Medical Center, Aurora, CO, ¹²VA Boston Healthcare System, Boston, MA, ¹³Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹⁴University of Utah/VA Salt Lake City Health Care, Salt Lake City, UT, ¹⁵UNIVERSITY OF UTAH, Salt Lake City, UT, ¹⁶University of Utah and Salt Lake City VA, Salt Lake City, UT
Background/Purpose: Administrative claims are often used to evaluate oral glucocorticoid (GC) use in RA for clinical and research purposes, despite limited evidence to support their…
Abstract Number: 1483 • ACR Convergence 2024
Real World Data on Infections from the Indian SLE Inception Cohort for Research (INSPIRE): Spectrum and Risk Factors
SAUMYA TRIPATHY¹, DEBASISH PANDIT², Sarit Pattanaik³, Liza Rajasekhar⁴, VINEETA SHOBHA⁵, Chengappa Kavadichanda⁶, Ashish J Mathew⁷, Parasar Ghosh⁸, Ranjan Gupta⁹, Manish Rathi¹⁰, AVINASH JAIN¹¹, MANOJ PARIDA¹², Bidyut Das¹³ and Amita Aggarwal¹⁴, ¹SCB Medical College, Cuttack, Odisha, India, Cuttack, Orissa, India, ²SJM MCH, Puri, Puri, Orissa, India, ³SCB Medical College and Hospital, Cuttack, Odisha, Cuttack, Orissa, India, ⁴Nizam's Institute of Medical Sciences, Madhapur, Andhra Pradesh, India, ⁵ST JOHN'S MEDICAL COLLEGE, BENGALURU, Karnataka, India, ⁶Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India, ⁷Christian Medical College, Vellore, Tamil Nadu, India, ⁸Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India, ⁹All India Institute of Medical Sciences, New Delhi, Delhi, India, ¹⁰Postgraduate Institute of Medical Education & Research, Chandigarh, Chandigarh, India, ¹¹SMS MCH, JAIPUR, JAIPUR, Rajasthan, India, ¹²SCB MEDICAL COLLEGE, CUTTACK, Cuttack, Orissa, India, ¹³SCB Medical College, Cuttack, Orissa, India, ¹⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Infections in SLE are a major cause of morbidity and mortality. The susceptibility to infections in SLE is multifactorial. Immune dysregulation, immunosuppressive drug use and…
Abstract Number: 2032 • ACR Convergence 2024
A Systematic Review of Treatment Strategies in VEXAS Syndrome
Aviraag Vijaya Prakash¹, Jose Garcia², Anurag Goel³, Vinit Gilvaz⁴ and Raveena Midha⁵, ¹Saint Vincent Hospital, Department of Internal Medicine, Worcester, MA, ²Brown University, East Greenwich, RI, ³The Warren Alpert Medical School of Brown University, Providence, RI, ⁴The Warren Alpert Medical School of Brown University, East Providence, RI, ⁵Kent Hospital/Brown University, Warwick, RI
Background/Purpose: VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome, first described in 2020, is an autoinflammatory condition characterized by somatic mutations in the UBA1 gene.…
Abstract Number: 2501 • ACR Convergence 2024
Long-term Remission off Therapy (LTROT) Is Possible in Non-infectious Aortitis with DMARDs with Low Risk of Secondary Adrenal Insufficiency
Rohit Vijjhalwar¹, Vithushanan Ketheeswaranathan², Aman More², Rajinder Andev³ and Shirish Dubey⁴, ¹University of Oxford, Staines, United Kingdom, ²Medical Sciences Division, University of Oxford, Oxford, United Kingdom, ³Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom, ⁴Oxford University Hospitals NHS FT, Oxford, United Kingdom
Background/Purpose: Non-infectious Aortitis is a rare form of large vessel vasculitis which has a high risk of complications1. There is limited data on the management…
Abstract Number: 0295 • ACR Convergence 2024
Mycophenolate Mofetil in the Treatment of Patients with Isolated Cardiac Sarcoidosis
Namitha Nair¹, Leen Al Saleh², Haya Haddad³, Maria Jaimes Reyes⁴, Vishakha Chetram⁵, Farooq Sheikh⁶, FLORINA CONSTANTINESCU⁷ and Anjani Pillarisetty⁸, ¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²Watson Clinic, Lakeland, FL, ³Medstar Washington Hospital Center, Silver Spring, MD, ⁴Medstar Washington Hospital Center/Georgetown University, Washington, DC, ⁵Inova Schar Heart and Vascular, Falls Chirch, VA, ⁶MedStar Heart and Vascular Institute, Georgetown University School of Medicine, Washington, DC, ⁷MedStar Washington Hospital Center, Washington, DC, ⁸Carson Tahoe Medical Group, Reno, NV
Background/Purpose: Cardiac involvement is seen in approximately a fourth of patients with sarcoidosis, a non-necrotizing granulomatous systemic disease. Among these patients, 25% may have isolated cardiac…
Abstract Number: 1495 • ACR Convergence 2024
Real-World Reduction in Disease Flares and Oral Corticosteroid Use with Anifrolumab Therapy in Systemic Lupus Erythematosus: A Claims-Based Study
Mawuena Binka¹, Rana Muhammad Qasim Khan², Joseph Tkacz³, Donna McMorrow³, Laurence Gozalo³ and Gail Kerr⁴, ¹BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, ²BioPharmaceuticals Medical, AstraZeneca, Wilmington, ³Inovalon, Bowie, MD, ⁴Veterans Affairs Medical Center, Georgetown and Howard University Hospitals, Washington, DC
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, chronic autoimmune disease characterized by frequent episodes of disease activity (flares) of varying severity.1 SLE flares are…
Abstract Number: 2139 • ACR Convergence 2024
Generation of a Human 3D Bone Model to Mimic Glucocorticoid- induced Osteoporosis In Vitro
Johannes Plank¹, Moritz Pfeiffenberger¹, Alexandra Damerau¹, Timo Gaber¹ and FRANK HARTMUT DR. BUTTGEREIT², ¹Charité-Universitätsmedizin Berlin, Deutsches Rheuma-Forschungszentrum Berlin (DRFZ), Berlin, Germany, ²Charité University Medicine Berlin, Berlin, Germany
Background/Purpose: Osteoporosis is a bone disease characterized by low bone mass and changes in bone architecture, often leading to pain, fractures and reduced mobility in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].